Vincerx Pharma, Inc.
VINCDelisted Apr 28, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796129
Vincerx Pharma, Inc. was delisted on Apr 28, 2025; its insiders filed their last Form 4 on Aug 14, 2024; 14 institutions reported holding it in 13F filings for Q1 2025, worth $116.8K in total; no superinvestor held it.
Q3 2023 vs. Q2 2023
How the institutions holding Vincerx Pharma, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 34 | 35 | +1 |
| Shares | 12.1M | 10.7M | −1.37M (−11.3%) |
| Value | $15.7M | $10.8M | −$4.87M (−31.0%) |
New holders (5)
Institutions that held Vincerx Pharma, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Price T Rowe Associates Inc | 40,000 | $42.0K | 0.00% |
| XTX Topco Ltd | 16,845 | $17.4K | 0.00% |
| UBS Group AG | 5,736 | $5.79K | 0.00% |
| FMR LLC | 6 | $6 | 0.00% |
| Qube Research & Technologies Ltd | 4 | $4 | 0.00% |
Sold out (4)
Institutions that held Vincerx Pharma, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Affinity Asset Advisors, LLC | 1,492,771 | $1.94M |
| Baker Bros. Advisors LP | 225,579 | $293.3K |
| Two Sigma Investments, LP | 10,446 | $13.6K |
| JPMorgan Chase & Co | 394 | $512 |